Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    ((2S,4S)-4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 906Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 13Canalia

    02 17Tenelia

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 222

    2019 Revenue in Millions : 230

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 137

    2019 Revenue in Millions : 112

    Growth (%) : 22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 80

    2019 Revenue in Millions : 69

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 200

    2020 Revenue in Millions : 220

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 139

    2020 Revenue in Millions : 136

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 138

    2019 Revenue in Millions : 147

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 84

    2020 Revenue in Millions : 79

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 133

    2020 Revenue in Millions : 137

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 170

    2021 Revenue in Millions : 200

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    The MedTech Conference
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    The MedTech Conference
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 116

    2021 Revenue in Millions : 128

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF